NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials
Last nantkwest, inc earnings: 3/25 04:09 pm
Check Earnings Report
US:NASDAQ Investor Relations: ir.nantkwest.com
Pivotal QUILT 88 trial based on combination immunotherapy of “Cancer Moonshot” strategy; early indications of increased survival rate for pancreatic cancer patients with no other approved treatment optionsIn initial Cancer Moonshot QUILT trials of haNK and avelumab (PD-L1 checkpoint inhibitor) completed in 2019, median overall survival rate more than doubled compared to historical controls (eight months versus three months)A complete remission was achieved when replacing haNK and PD-L1 checkpoint inhibitor avelumab with PD-L1 t-haNK and four out of five patients are alive 8-16 months since beginning treatment on these expanded protocolsBased on this encouraging early data, a single-arm Phase 2 study (QUILT 88, Cohort C) was initiated in October 2020, for which the primary endpoint is overall survival and 15 out of 18 (83%) of patients enrolled with second-line or greater pancreatic cancer remain alive to dateRandomized trials in first- and second-line pancreatic cancer are actively re
[Read more]
| Impact snapshot | Event time: | NK | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
NK alerts
NK alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NK alerts
High impacting NantKwest, Inc news events
Weekly update
A roundup of the hottest topics
NK
News
- SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following MergerPR Newswire
- CytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer PatientsBusiness Wire
- NantKwest is up in pre-market as Piper Sandler remains bullish on stock [Seeking Alpha]Seeking Alpha
- SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigations of NK, RNET, HMSY, and QEP MergersGlobeNewswire
- SHAREHOLDER ALERT: WeissLaw LLP Reminds WTRE, TNAV, RNET and NK Shareholders About Its Ongoing InvestigationsPR Newswire
- More
NK
SEC Filings
- 1/13/21 - Form 425
- 1/13/21 - Form 4
- 1/13/21 - Form 8-K
- NK's page on the SEC website
- More